



EluNIR-PERL™

Ridaforolimus Eluting Coronary Stent System

LESS IS MORE


translumina
LIMITLESS POSSIBILITIES

 **Medinol®**
Ingenuity for life


EluNIR - PERL™ WiZeCell™

Dual Pattern strut stent design

Excellent Conformability and Scaffolding




Optimal Drug Deposition



Uniform cell sizes prevents tissue prolapse & ensures uniform drug deposition


Low Metal Footprint - 40% Less Metal Load




*Data on File

EluNIR - PERL™ Spring Tip & Radiopaque Markers

Redefining Deliverability and Visibility



Hybrid Spring Tip Design - Superior Deliverability





Tip Integrates Metal
+ Nylon Jacket
Improves Radiopacity
& Crossability

Enhanced TIP Visibility, Flexibility
& Pushability



No “Fish-Mouth” effect with the enhanced hybrid metal spring tip even in extreme vessel curvatures.

Proximal & Distal Radiopaque Stent Markers



Positioning: Accurate Stent Deployment

Precision: Aids Post- Dilatation and Bifurcation Stenting


Visualization: Shorter procedure times and reduced radiation,
optimal for **ostial lesions**

EluNIR - PERL™ Drug Selectivity & Coating Perfection




Ridaforolimus Precision with Superior Coating Integrity

Setting a new benchmark with Ridaforolimus



- Ridaforolimus offers the best balance, effectively stopping Smooth Muscle Cells while allowing Endothelial Cells to survive.




- Excellent choice for drug-eluting stents.



Elastomeric Coating - Improved Surface Quality**

- The elastomeric coating resists cracking, peeling and flaking, promoting long term coating integrity
- The unique coating composition of EluNIR-PERL enables a predictable and uniform release of Ridaforolimus, a Rapamycin analogue

Coating irregularities in competitive stents**



Xi_n_e

Sy_e_gy

Re_o_u_e

Images taken by Medinol using scanning electron microscope


*Data on File ** Elastomer - High Elasticity Polymer

EluNIR - PERL™ Family Outstanding Clinical Outcomes


Clinically Validated Outcomes Across BIONICS and NIREUS

Pooled BIONICS and NIREUS Clinical Outcomes


TLF



ST




MI





Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents 2-Year Clinical Outcomes from the BIONICS and NIREUS Trials.

Dilatation Limits*




Side Branch Access



*Data on File

EluNIR-PERL™

Ridaforolimus Eluting Coronary Stent System



Ordering Information



Stent Diameter (mm)	Stent Length (mm)				
	8	12	15	17	20
2.25	ELM225R08IN	ELM225R12IN	ELM225R15IN	ELM225R17IN	ELM225R20IN
2.50	ELM250R08IN	ELM250R12IN	ELM250R15IN	ELM250R17IN	ELM250R20IN
2.75	ELM275R08IN	ELM275R12IN	ELM275R15IN	ELM275R17IN	ELM275R20IN
3.00	ELM300R08IN	ELM300R12IN	ELM300R15IN	ELM300R17IN	ELM300R20IN
3.50	ELM350R08IN	ELM350R12IN	ELM350R15IN	ELM350R17IN	ELM350R20IN
4.00	ELM400R08IN	ELM400R12IN	ELM400R15IN	ELM400R17IN	ELM400R20IN

Stent Diameter (mm)	Stent Length (mm)				
	24	28	33	38	44
2.25	ELM225R24IN	ELM225R28IN	ELM225R33IN		
2.50	ELM250R24IN	ELM250R28IN	ELM250R33IN		
2.75	ELM275R24IN	ELM275R28IN	ELM275R33IN	ELM275R38IN	ELM275R44IN
3.00	ELM300R24IN	ELM300R28IN	ELM300R33IN	ELM300R38IN	ELM300R44IN
3.50	ELM350R24IN	ELM350R28IN	ELM350R33IN	ELM350R38IN	ELM350R44IN
4.00	ELM400R24IN	ELM400R28IN	ELM400R33IN	ELM400R38IN	ELM400R44IN

References: **1. EluNIR :** JACC Cardiovasc Interv. 2020 Jan 13;13(1):86-93. doi: 10.1016/j.jcin.2019.08.019. Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes from the BIONICS and NIREUS Trials.

2. Xience: ABSORB III. Ellis et al.; Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease; N Engl J Med 2015; 373:1905-1915. **Orsiro:** BIOFLOW V. Kandzari et al.; Ultrathin Bioresorbable Polymer Sirolimus- Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularisation; A randomized trial. The Lancet 2017. Synergy: EVOLVE II. Kereiakes et al.; Efficacy and Safety of a Novel Bioabsorbable Polymer- Coated, Everolimus-Eluting Coronary Stent; Circulation 2015; 8:e0023272. **3.** Paradies V. et al. A prospective randomized trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: 6 months angiographic and 1 year clinical results of the NIREUS trial; EuroIntervention 2018; 14:86-93. **4.** Basalus et al., Eurointervention 2013; 9:302-305.

Prior to use, refer to the "Instructions For Use" supplied with this device for indications, contraindications, side effects, suggested procedure, warning and precautions.

EluNIR-PERL is FDA approved (44mm lengths are not approved in the United States). For information on other countries please contact Medinol. © Medinol Ltd. 2023 MKB2016-2

Manufactured By:
Medinol Ltd.
Building 8, Kiryat Atidim,
Tel Aviv, 6158101, Israel
Tel: +972-3-767-9000

Medinol, USA Inc
13395 Voyager Pkwy, Suit 130-125
Colorado Springs, CO 80921, USA
Email: contact@medinol.com
www.medinol.com

Marketed By:
Translumina Therapeutics Pvt. Ltd.
Regd. Off: BPTP Capital City,
7th Floor, Sector 94, Noida,
Uttar Pradesh 201301

